Clinical Trials, Phase I as Topic
"Clinical Trials, Phase I as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.
| Descriptor ID |
D017321
|
| MeSH Number(s) |
E05.318.760.250.500.200 N05.715.360.775.088.500.200 N06.850.520.450.250.250.200
|
| Concept/Terms |
Microdosing Trials, Human- Microdosing Trials, Human
- Human Microdosing Trial
- Microdosing Trial, Human
- Trial, Human Microdosing
- Trials, Human Microdosing
- Human Microdosing Trials
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase I as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase I as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase I as Topic" by people in this website by year, and whether "Clinical Trials, Phase I as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 8 | 11 | 19 |
| 2018 | 3 | 13 | 16 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 4 | 7 |
| 2021 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials, Phase I as Topic" by people in Profiles.
-
CureVac COVID vaccine let-down spotlights mRNA design challenges. Nature. 2021 06; 594(7864):483.
-
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021 06; 594(7862):253-258.
-
Crocetin and related oxygen diffusion-enhancing compounds: Review of chemical synthesis, pharmacology, clinical development, and novel therapeutic applications. Drug Dev Res. 2021 11; 82(7):883-895.
-
Plitidepsin: a Repurposed Drug for the Treatment of COVID-19. Antimicrob Agents Chemother. 2021 03 18; 65(4).
-
SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Lancet Oncol. 2021 03; 22(3):298-301.
-
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Trials. 2021 Feb 05; 22(1):116.
-
Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. Asia Pac J Clin Oncol. 2021 Aug; 17(4):388-395.
-
Audio Interview: Vaccinology and Covid-19. N Engl J Med. 2020 10 15; 383(16):e109.
-
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium. Eur J Cancer. 2020 12; 141:82-91.
-
Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol. 2020 Oct 15; 885:173494.